Progesterone (PG), a female hormone, alters ERα chromatin binding events in malignant breast cancer through progesterone receptor (PGR), which changes gene expression patterns, and the administration of PG reduced E2-dependent tumor growth in mouse xenograft experiments with MCF-7 cells (Mohammed et al., 2015). The gene discussed is ESR1; the disease is neoplasm.